News - Vanda Pharmaceuticals, Isis Pharmaceuticals

Filter

Popular Filters

1 to 25 of 30 results

FDA approves Hetlioz, first treatment for non-24 hour sleep-wake disorder in blind people

FDA approves Hetlioz, first treatment for non-24 hour sleep-wake disorder in blind people

03-02-2014

The US Food and Drug Administration on Friday approved US drugmaker Vanda Pharmaceutical's Hetlioz (tasimelteon),…

HetliozNeurologicalPharmaceuticalRare diseasesRegulationVanda Pharmaceuticals

Positive FDA panel recommendation for Vanda’s tasimelteon

Positive FDA panel recommendation for Vanda’s tasimelteon

15-11-2013

The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee…

HetliozNorth AmericaOphthalmicsPharmaceuticalRegulationtasimelteonVanda Pharmaceuticals

Isis Pharma earns $10 million milestone in deal with Biogen

16-10-2013

Isis Pharmaceuticals says that it has earned a $10 million milestone payment from fellow USA-based biotech…

Biogen IdecBiotechnologyFinancialIsis PharmaceuticalsISIS-DMPKrxRare diseasesResearch

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Biogen Idec and Isis Pharma collaborate in $100 million upfront deal

10-09-2013

US biotech firms Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

Mixed Ph II results with Isis-CRPRx in RA patients

05-08-2013

US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) says that patients treated with ISIS-CRPRx achieved…

Anti-Arthritics/RheumaticsBiotechnologyIsis PharmaceuticalsIsis-CRPrxResearch

Isis Pharma stock leaps, as investigational drug shown to reduce triglycerides in Ph II study

25-06-2013

US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) saw its shares leap as much as 22% to $26.89 on Monday,…

BiotechnologyCardio-vascularDiabetesIsis PharmaceuticalsISIS-APOCIIIrxResearch

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard

10-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

$10M milestone for Isis Pharma from AstraZeneca for ISIS-ARRx to treat prostate cancer

04-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says that Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AstraZenecaIsis PharmaceuticalsISIS-AR rxLicensingOncologyPharmaceutical

Roche and Isis Pharma in up to $392 million deal on Huntington's research

09-04-2013

Swiss drug major Roche (ROG: SIX) and USA-based Isis Pharmaceuticals (Nasdaq: ISIS) have formed an alliance…

Isis PharmaceuticalsLicensingMarkets & MarketingPharmaceuticalRare diseasesResearchRoche

Vanda Pharma pulls EU application for schizophrenia drug candidate Fanaptum

15-03-2013

The European Medicines Agency has been formally notified by USA-based Vanda Pharmaceuticals (Nasdaq:…

EuropeFanaptumNeurologicalPharmaceuticalRegulationVanda Pharmaceuticals

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Vanda's tasimelteon meets primary endpoint in Ph III study

18-12-2012

Shares of USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) moved 2.8% higher to $3.22 in early trading…

NeurologicalPharmaceuticalResearchtasimelteonVanda Pharmaceuticals

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions

17-12-2012

French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

Biogen Idec and Isis Pharma in up to $230 million antisense deal

11-12-2012

USA-based companies Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy

02-07-2012

In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Vanda gains rights to Lilly's NK-1 receptor antagonist

17-04-2012

USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) said yesterday that it has acquired an exclusive worldwide…

Eli LillyLicensingNeurologicalPharmaceuticalVanda Pharmaceuticals

Genzyme and Isis file Kynamro NDA in USA

02-04-2012

Biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), has submitted a New Drug…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

1 to 25 of 30 results

Company Spotlight

Fibrotech

Fibrotech

Back to top